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Background
Recent studies have shown that TGF-β1 may have an important role in gastric cancer progression and metastasis. However, the role of TGF-β1 in lymph node metastasis and lymphangiogenesis, one of the most important steps of gastric cancer dissemination, is largely unknown. The goal of this study was to investigate the role of TGF-β1 signaling in gastric cancer and the molecular mechanisms involved in lymphangiogenesis.
Methods
Two gastric cell line models, MKN45 and KATOIII, were selected for this study. The potential role of TGF-β1 signaling in in vitro lymphangiogenesis was investigated. The expression of TGF-β1 pathway molecules and VEGF-C, a representative prolymphangiogenic factor, was examined by RT-PCR, western blot, or ELISA in response to the TGF-β1 and TGF-β1 receptor I inhibitor treatment. To elucidate whether Smad3 binds to the specific DNA sequences in the VEGFC promoter, we performed an electrophoretic mobility shift assay (EMSA). The cell line-specific effects of the Smaddependent and Smad-independent pathways on lymphangiogenesis were also examined.
Tube formation of lymphatic endothelial cells was assayed on a matrigel to evaluate TGF-β1-activated tumor cell-stimulated lymphangiogenesis.
Results
Two gastric cell line models, MKN45 and KATOIII, showed functional regulation of TGF-β1 signaling pathway. Conditioned media of both cells were able to induce the TGF-β1 signaling pathway in a cell line which only expresses TGF-β receptor II. TGF-β1 induced activation of Smad2/3 and Smad pathway-modulated VEGF-C expression.
Phosphorylated and activated Smad3 in the nucleus bound to the promoter of VEGFC in KATO III cells. Of note, in MKN45 cells, the Smad-independent AKT pathway was also activated in response to TGF-β1 and induced VEGF-C expression. Inhibition of TGF-β1 signaling down-regulated the expression of VEGF-C and blocked tube formation of lymphatic endothelial cells in vitro.
Conclusion
TGF-β1 signaling may promote in vitro lymphangiogenesis through VEGF-C production in gastric cancer cells. Cell line-specific Smad-dependent and -independent pathways were able to induce the expression of VEGF-C and enhance tube formation of lymphatic endothelial cells.
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I. INTRODUCTION
Gastric cancer
In 2012, gastric cancer was responsible for 723,000 deaths and was ranked as the world's third leading cause of cancer mortality. 1 Gastric cancer is also the second most common malignancy in Korea. 2 Regional lymph nodes are the most common site of tumor spread, and lymph node metastasis is a major prognostic factor for gastric carcinomas. Thus, understanding the mechanism of lymphatic metastasis is crucial toward bringing a new therapeutic strategy to the treatment of gastric cancer.
Although conventional chemotherapy has improved the overall prognosis of gastric cancer, the survival rate of patients with advanced cancer still falls short of expectations. With recent advances in our understanding of the molecular basis of this deadly disease, deregulated cellular pathways have been identified and targeted, providing new therapeutic options beyond conventional chemotherapies.
Indeed, human epidermal growth factor receptor 2 (HER2) and vascular endothelial growth factor receptor 2 (VEGFR2) have been evaluated as therapeutic targets and are now available as treatment regimens in metastatic gastric cancer.
3,4
Lymph node metastasis and lymphangiogenesis
Recent studies suggest that lymphangiogenesis, the formation of new lymphatic vessels induced by tumors, is directly correlated with lymph node metastasis in gastric cancer. [5] [6] [7] The most studied lymphangiogenic signaling system is the vascular endothelial growth factor-C (VEGF-C)/VEGF-D and VEGF receptor 3 (VEGF-R3) signaling axis, which play a central role in lymphangigoenesis in animal models. Elevated expression of VEGF-C and VEGF-D has been observed in gastric cancer. [8] [9] [10] [11] [12] 3. The importance of TGF-β1 in gastric cancer biology
Data from one multicenter transcriptome study 13 and The Cancer Genome Atlas 14 have established the significance of transforming growth factor beta 1 (TGF)-β1 signaling on gastric cancer progression.
These support its role as an emerging candidate biomarker for gastric cancer. In line with these pivotal studies, others also have shown the relation between high expression of TGF-β1 and unfavorable prognosis of gastric cancer patient. [15] [16] [17] [18] Our pilot study of mRNA transcriptome microarray data also showed that gastric cancer patients with a higher level of TGF-β receptor 2 (TβRII) experience a poorer survival rate ( Figure 1 ). Figure 1 . 158 mRNA microarray data of gastric cancer. Gastric cancer patients with higher TβRII expression (CL2_2, red line) show a poor prognosis compared to those with lower expression. TβRII, TGF-β receptor 2.
Transforming growth factor-β (TGF-β) signaling
TGF-β signals through a complex network of transduction pathways and has important roles in embryonic development, cell proliferation, differentiation, angiogenesis, and wound healing. TGF-β belongs to a family of dimeric peptide growth factors that induces bone morphogenetic proteins (BMPs), activins, and inhibins. 19 The isoforms of TGF-β ligand are TGF-β1, TGF-β2, and TGF-β3.
TGF-β1 is expressed in epithelial, endothelial, hematopoietic, and connective tissue cells. TGF-β2 is expressed in epithelial and neuronal cells. TGF-β3 is expressed primarily in mesenchymal cells. 20 There is 70%-80% homology among TGF-β ligand isoforms, which have different binding affinities to their receptors in a tissue-specific manner. 21 TGF-β ligand is synthesized as a large precursor molecule that contains a latent TGF-β binding protein region, which is stored in the extracellular matrix. Latent TGF-β can be activated by thrombospondin-1 22 and the integrin αvβ6 23 to release the mature TGF-β protein, which can bind TGF-β receptors and stimulate a response.
The TGF-β ligand signals through type I and II TGF-β receptors (TβRI and TβRII, respectively).
There are seven TβRIs and 5 TβRIIs that provide a receptor system for the whole family of TGF-β ligands. 24 These receptors contain a serine/threonine kinase domain within the cytoplasmic domain.
TGF-β ligand signals through TβRII, which recruits and phosphorylates the TβRI kinase domain. The membrane-bound TβRIII (β-glycan) assists TGF-β direct ligation to TβRII by forming a high affinity ternary complex. 25 This results in recruitment and phosphorylation of the downstream mediators Smad2 and Smad3. Phosphorylated Smad2 and Smad3 combine with Smad4 and enter the nucleus.
This Smad complex recruit coactivators, repressors, and chromatin remodeling factors to regulatory regions of target genes in specific cells in a context-dependent fashion. Samd7 is a negative regulator of the Smad signaling pathway.
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In addition to Smad-dependent signaling, the binding of TGF-β to its receptors activates many noncanonical signaling pathways, such as the phosphoinositol-3 kinase (PI3K), mitogen-activated protein kinase, and small guanosine triphosphatase pathways. 27 Theses pathways most often are implicated in tumor cell motility and migration. 28 
TGF-β1 and lymphangiogenesis
TGF-β1 is known to play a critical role in the malignant progression of various tumors. Tumorstimulated lymphangiogenesis is required for regional lymph node metastasis of cancer cells. It is believed that the interaction between tumor cells and their microenvironment is important in lymphangiogenesis, as it similarly is in angiogenesis. Recent studies suggest that TGF-β1 signaling in tumor cells may promote lymphangiogenesis by producing a key prolymphangiogenic growth factor, VEGF-C. 29 Although the precise mechanisms of TGF-β signaling in lymphangiogenesis in various tumor types need to be further elucidated, there are controversial results suggesting dual or contradictory roles in lymphangiogenesis. [30] [31] [32] [33] TGF-β signaling may be involved in the expression of VEGF-C in certain types of cells thereby promoting tumor lymphagiogenesis. 29, 34 In contrast, TGF-β has been reported to downregulate VEGFR-3, the cognate receptor of VEGF-C, in lymphatic endothelial cells leading to the suppression of lymphangiogenesis. 30 Given that TGF-β1 is secreted and instigates TGF-β1-induced signaling pathways both in tumor cells and lymphatic endothelial cells,
it remains unclear what would be the collective effects of TGF-β on tumor lymphangiogenesis.
The overarching goal of this study
Although the role of TGF-β in angiogenesis has been known to some extent, 35, 36 its role on lymphangiogenesis has not been well elucidated, 30, 32, 33 especially in the field of gastric cancer. We hypothesized that TGF-β signaling in cancer cells plays an important role in lymphangiogenesis via expression of prolymphangiogenic factor VEGF-C, which enhances lymphatic tube formation. The aim of this study was to investigate the role of TGF-β1 signaling on lymphangiogenesis and its molecular mechanisms in gastric cancer cell line models.
II. MATERIALS AND METHODS
Cell culture
The human gastric cancer cell lines AGS, MKN28, MKN45, NCI-N87, SK4, KATOIII, HS746T, and
YCCs were cultured in RPMI 1640 medium (Hyclone, South Logan, Utah) containing 10% fetal bovine serum, 100 U/ml of penicillin sodium, and 100 ㎍/ml of streptomycin sulfate at 37°C in a humidified incubator containing 5% CO2. Cultured human lymphatic endothelial cells (HLECs) were purchased from Promo Cell (Promo Cell, Heidelberg, Germany). This cell line was maintained in complete medium (Endothelial cell growth medium 1; Promo Cell, Heidelberg, Germany) on gelatincoated dishes. HLECs were used between passages 5 and 8.
Western blot analysis
Gastric cancer cells were collected and lysed on ice for 30 min in lysis buffer [1% Triton X-100, 50 mmol/L HEPES (Ph 7.5), 150 mmol/L NaCl, 25mmol/L β-glycerophosphate, 25 mmol/L NaF, 5 mmol/L EGTA, and 1 mmol/L EDTA as a protease inhibitor cocktail (Roche Diagnostic, Indianapolis, IN)]. The lysates were clarified by centrifugation for 13,000 rpm for 30 min. Equal amounts of protein were loaded onto a sodium dodecyl sulfate-polyacrylamide gel (12% polyacrylamide) followed by electrophoresis at 100 V for 3 h and transferred to polyvinylidene floride membrane at 100 V for 1 h.
Subsequently, the PVDF membrane was incubated in TBS-T with 5% skim milk (blocking solution)
for 1 h at room temperature. The PVDF membrane was subsequently incubated 4°C overnight with the target primary antibody. Anti-TGFRII, Smad3, Erk, Akt, TAK1, VEGF-C (dilution 1:1000; cell signaling Technology, Massachusetts, USA) and anti-β-actin (dilution 1:1000; Sigma-Aldrich, USA)
antibodies were diluted in TBS-T (TBS/Tween 20: 2% skin milk). The appropriate secondary antibodies were applied (1:5000, horseradish peroxidase-conjugated anti-rabbit and anti-mouse) at room temperature for 1 h. Labeled bands were detected by enhanced chemiluminescence (ECL;
ThermoScientific, USA).
Electrophoretic mobility shift assay (EMSA)
The DNA binding activity of Smad3 against the VEGFC promoter was investigated using a 32P- 
Tube formation assay
HLECs (1×10 5 ) were cultured in a 24-well plate coated with 150 μl of Growth factor-reduced Matrigel in MVI1 medium for cell attachment for 1 h. The MVI medium was replaced with conditional medium and continuous cell culture for 24 h. Tube length was quantified after 8 h by measuring the total cumulative tube length in three random microscopic fields with a computerassisted microscope using NIH ImageJ1.44 image analysis software, which is available at http://rsb.nih.gov/nih-image. The original magnification used was x100.
Enzyme-linked immunosorbent assay (ELISA)
Protein content in culture medium was determined using the Quantikine Immunoassay systems for human VEGF-C ELISA kit (R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions. ELISA data analysis (target protein content in culture medium) was expressed as the quantity of protein secreted from 10,000 cells for 24 h.
Statistical analysis
Values are expressed as means ± S.D. Mann-Whitney test was used to evaluate the data. Differences were considered to be statistically significant at P<0.05. All analyses were performed using SPSS 21 software (SPSS, Chicago, IL).
III. RESULTS
Selection of model cell lines
To select model cell lines suitable for testing the hypothesis, we examined the expression of TGF-β1, TβR2, TGF-β receptor 2
The paracrine regulation of TGF-β1 in gastric cancer cells.
We further investigated additional gastric cancer cell lines and found that YCC2 and YCC3 only express a significant level of TGF-β1 receptor II, but not TGF-β1 ( Figure 3A) . We ascertained the existence of TGF-β1 in conditioned media of MKN45 and KATOIII but not in YCC2 ( Figure 3B ). We noticed that Smad2 and Smad3, the receptor activated Smads (R-Smads), were phosphorylated and activated in YCC2 cells when treated with the conditioned media of MKN45 and KATOIII ( Figure   3C ). Therefore, we confirmed the paracrine effect of TGF-β1 signaling in certain gastric cancer cell lines. production (A, B). Smads were detected only in the total cell lysate of YCC2, which was cultured in the conditioned media of MKN45 and KATOIII cells (C).
The TGF-β1 signaling pathway in gastric cancer cells
To confirm the validity of these model cell lines for TGF-β1 responsiveness, MKN45 and KATOIII cells were treated with TGF-β1 (10 ng/ml) and were analyzed for target gene expression. As shown in Figure 4A , the mRNA expression of twist1, a well-established target gene of the TGF-β1 signaling pathway, was significantly induced by TGF-β1 treatment in both cell lines. In addition, the corresponding increase of phosphorylation of Smad3 was evident in TGF-β1-treated cells ( Figure 4B ).
Further, the treatment of TGF-β1 receptor inhibitor (LY2157299) abrogated the effect of TGF-β1-induced phosphorylation of Smad3, confirming intact and functioning TGF-β1 signaling in these cell lines ( Figure 4C ). 
The downstream signaling of TGF-β1 in gastric cancer cells
To investigate the effect of TGF-β1 on the expression of VEGF-C, we treated KATO III cells with TGF-β1 and/or TGF-β1 receptor I inhibitor (LY2157299), as indicated. In KATOIII cells, the expression of phosphorylated form Smad3 (p-Smad3), not p-Smad2, was down-regulated in response to TGF-β1 receptor I inhibitor (LY2157299). The inhibitory response was correlated positively in a dose-related manner ( Figure 5A ). In addition, to elucidate the nuclear localization of activated Smad3 in response to TGF-β1, we examined the expression level of both p-Smad3 and total form Smad3 (tSmad3) in nucleus and cytosol according to the treatment of TGF-β1 and LY2157299. The expression of p-Smad3 in the nucleus was increased with TGF-β1, while it was decreased with LY2157299
( Figure 5B ). 
The binding interaction between Smad3 and the VEGFC promoter
To elucidate whether TGF-β1 signaling-induced lymphangiogenesis is mediated through increased transcription of VEGF-C, we first investigated the interaction between transcription regulator Smad3 and the promoter region of VEGFC. A few Smad3 binding sites have been identified in the VEGFC promoter region. 29, 37, 38 We carried out an EMSA with a 32 P-labeled oligonucleotide containing Smad3 binding sites found in the VEGFC promoter ( Figure 6A ). Labeled Smad3 probe-nuclear extract (from the MKN45 and KATO III cells) complexes produced two bands. The specificity of the EMSA result was confirmed by complete inhibition of Smad3 DNA binding by excess labeled and unlabeled Smad3 (lane 1, Figure 6B ). In addition, a similar amount of mutated Smad3 probe also failed to bind to the Smad3 transcription complex (lane 2, Figure 6B ).
In KATOIII cells (lane 4 and 6, Figure 6B ) Smad3 binding activity to the VEGFC promoter region was significantly increased compared to that in MKN45 cells (lane 3 and 5, Figure 6B ). The binding signals were increased with five times more nuclear extract alone (lane 7 and 8, Figure 6B ). To assure the binding interaction between Smad3 and the promoter of VEGFC, a super-shift assay with antiSmad3 antibody was performed and showed more potentiated signals (lane 9 and 10, Figure 6B ).
Furthermore, that response was promoted with more concentrated nucleic extract (lane 11 and 12, Figure 6B ). Together, these results demonstrate that Smad3 can bind to the promoter of the VEGFC gene. 
Inhibition of TGF-β1 signaling suppresses VEGF-C expression
Next, we examined whether the inhibition of TGF-β1 signaling in model cell lines suppresses VEGF-C expression. By western blot analysis of conditioned media of KATO III and MKN45 cells, we demonstrated that the protein level of VEGF-C is decreased when treated with LY2157299 ( Figure 7 ).
Based on these results, we confirmed that TGF-β1 signaling promotes VEGF-C expression in gastric cancer cells. 
Smad-independent pathway of TGF-β1 in gastric cancer cells
According to the EMSA results, the binding interaction between Smad3 and the VEGFC promoter region is lower in MKN45 than KATOIII cells. These findings may suggest the existence of other TGF-β1 signaling pathways for VEGF-C activation, which are different from the Smad-dependent pathway. Therefore, we examined Smad-independent signaling pathway molecules. Among them, phosphorylated Akt (p-Akt) was remarkably induced in response to TGF-β1 treatment only in MKN45 cells ( Figure 8A ). The expression of p-Akt was increased when treated with TGF-β1, but decreased when treated with its inhibitor LY2157299 in MKN45 cells ( Figure 8B ).
Taken together, TGF-β1 signals may be transduced through Smad-dependent and Smad-independent pathways in accordance with gastric cancer cell line characteristics. 
Lymphatic endothelial cell tube formation
Next, we validated the effect of TGF-β1 signaling on lymphangiogenesis by conducting a lymphatic endothelial cell tube formation assay. HLECs were cultured in the conditioned media of MKN45 and KATOIII cells. After 18 h of culture, we noticed the formation of a tubular structure of HLECs in MKN45-and KATOIII-conditioned media compared to HLECs alone or in YCC2-conditioned media ( Figure 9 ). In addition, the tubule forming ability of HLECs was decreased when treated with the conditioned media of tumor cells treated with TGF-β receptor 1 inhibitor (LY2157299). Quantitation of the results was confirmed by measuring the length of tube formation of HLECs ( Figure 10 ). The expression level of secreted VEGF-C in YCC2-, MKN45-, and KATOIII-conditioned media according to the treatment of TGF-β1 and LY2157299 was also investigated by ELISA analysis. The level of VEGF-C was increased for TGF-β1, whereas it was decreased for LY2157299 ( Figure 11 ). Recent studies in gastric cancer 13, 14 and expected favorable results of a clinical trial for hepatocellular carcinoma 39 have intensified an interest in the role of TGF-β1 in gastric cancer biology. TGF-β1 has been known to have a distinct biphasic role in tumor progression. It functions as a tumor suppressor in early stages of cancer, while a tumor promoter in late stages. 24 This dual role of TGF-β1 on tumor biology makes it difficult to understand its mechanism and to apply it therapeutically to a clinical setting. In addition, the reciprocal relation between cancer and surrounding stromal cells, such as lymphocytes, macrophage, fibroblast, etc., makes the situation more complex and complicated.
Among many other oncogenic effects of TGF-β1, the role for Epithelial-mesenchymal transition (EMT) has been studied most thouroughly. 24 However, the role of TGF-β1 on lymphangigoenesis is largely unknown, despite the fact that lymphangiogenesis and lymph node metastasis is the most important prognostic factor in gastric cancer. Although the relation between TGF-β1 and tumor lymphangiogenesis has not been well elucidated, recent studies suggest that TGF-β1 might upregulate VEGF-C expression in some types of cells, including tumor cells, implying that TGF-β1 signaling might contribute to tumor lymphangiogenesis. 29 Conversely, TGF-β1 has been found to downregulate VEGF receptor-3 (VEGFR3) in HLECs and suppress HLEC properties, thus inhibiting lymphangiogenesis. 34 So far the effect of TGF-β1 on HLECs and the final effect of TGF-β1 on tumor lymphangiogenesis remains unclear, especially for gastric cancer. Therefore, it is important to elucidate the role of TGF-β1 for lymphangiogenesis in gastric cancer. In this regard, our study may contribute to providing potential evidence for the role of TGF-β1 signaling in lymphangiogenesis regulation in gastric cancer cell models. The data in this study suggest that TGF-β1 signaling can upregulate VEGF-C expression, which leads to lymphangiogenesis in gastric cancer. The signals of TGF-β1 to transcriptional induction of VEGF-C can be mediated via canonical Smad3 in some gastric cancer cells, while it can also be conveyed via the non-canonical Smad-independent AKT pathway. Of note, LY2157299 which is used in this study as a TβR1 small molecule inhibitor might inhibit both Smad-dependent and Smad-independent pathways, because both pathways are downstream of the common upstream complex of TGF-β1 and TβR1. 24 Thus, the results signify that LY2157299 can be a new therapeutic agent against gastric cancer progression and metastasis regardless of which pathways being activated. This has been tested in a phase II clinical trial of a target therapy for hepatocellular carcinoma (NCT01246986). 40 In MKN45 cells, but not in KATOIII cells, TGF-β1 signaling increases the expression of p-Akt, while inhibition of TGF-β1 signaling decreases it. Our previous results showed that activated p-Akt inhibits 핵심되는 말: TGF-β1, 림프관신생, 위암
